Combinations and Treatment Sequence Strategies in Breast Cancer
July 22nd 2024In their discussion, the key opinion leaders explore the potential of combination therapies in HR+/HER2- metastatic breast cancer, with a specific focus on the ELECTRA study, which investigated the combination of elacestrant and abemaciclib.
Read More
PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors
July 22nd 2024The expert panel examines the subgroup data from the postMONARCH study, focusing on patients with ESR1 and PIK3CA mutations, and emphasizes the important role of CDK4/6 inhibitors in the treatment of these specific patient populations with HR+/HER2- metastatic breast cancer.
Read More
PIK3CA Mutations and Delivering PI3K Inhibitors
July 15th 2024In their discussion, the key opinion leaders explore the significance of PIK3CA mutations in HR+/HER2- metastatic breast cancer and review the findings from two pivotal clinical trials, SOLAR-1 and CAPItello-291, which investigated the efficacy of targeted therapies in patients harboring these mutations.
Read More
Case Presentation 2: Co-mutations in ESR1 and PIK3CA
July 15th 2024Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, discuss the clinical presentation and management of a 64-year-old postmenopausal female with a history of rheumatoid arthritis who was diagnosed with stage IV, grade 3, invasive ductal carcinoma in her left breast, taking into account her comorbidities and the advanced stage of her breast cancer.
Read More
Evolving Best Practices for ESR1 Testing
July 8th 2024The breast cancer experts share their clinical experiences and strategies regarding the optimal timing for testing ESR1 mutations in patients with HR+/HER2- metastatic breast cancer, elaborating on how the specific points in the treatment journey at which they recommend testing influence their subsequent treatment decisions and overall approach to patient management.
Read More
EMERALD Study Design and Results for Elacestrant
July 8th 2024Key opinion leaders examine the EMERALD trial, which evaluates the efficacy of elacestrant in patients with HR+ HER2- metastatic breast cancer, focusing on the subgroup analysis of patients with visceral metastases, and explore how the trial's design and results have influenced their clinical practice.
Read More
Case Presentation 1: PIK3CA Mutation With ESR1 Mutations
July 1st 2024Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, present a patient case involving a 54-year-old postmenopausal woman diagnosed with a 2.1cm estrogen receptor positive (ER+), HER2 negative breast cancer, and discuss the clinical implications and management strategies for this specific patient scenario.
Read More
Dynamics of ESR1 Alterations and Serial Liquid Biopsies
July 1st 2024In their discussion, medical experts in the field of breast cancer explore the role of liquid biopsies and compare the significance of ESR1 mutations to other biomarkers, such as PIK3CA, in terms of their driver versus passenger status in the context of HR+/HER2- breast cancer.
Read More
Evolution of Testing Strategies for ESR1
June 25th 2024The key opinion leaders (KOLs) review the current testing methods for detecting ESR1 mutations and explore the existing strategies employed to overcome or delay the development of these mutations and the associated endocrine resistance in patients with HR+/HER2- metastatic breast cancer.
Read More
Prevalence and Testing Strategies for ESR1
June 25th 2024Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, explore the clinical significance of *ESR1* mutations in HR+/HER2- metastatic breast cancer patients, including their impact on disease prognosis, treatment outcomes, and the increasing prevalence of these mutations with each line of endocrine therapy, ultimately informing their therapeutic approach.
Read More
The Future of HER2+ Breast Cancer Treatment
Panelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.
Read More
Patient Profile 3: Metastatic HER2+ BC
Dr Kaklamani presents a profile of a patient with HER2+ breast cancer and liver metastases who had disease progression after first-line chemotherapy and a solitary new brain metastasis after second-line T-DM1.
Read More
Patient Profile 2: Early Stage HER2+/HR- BC
Melinda L. Telli, MD, presents a profile of a patient with early stage breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery, whose tumor was initially HER2+ but became triple-negative after treatment.
Read More
Patient Profile 1: Early Stage HER2+/HR+ BC
Virginia G. Kaklamani, MD, DSc, presents a patient profile of early stage HER2+ breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery.
Read More
Typical Approaches for Treatment Selection in the Third Line and Beyond
Experts share their go-to regimens in the third-line and higher setting of HER2+ metastatic breast cancer, and touch on the factors that support their decision-making.
Read More
HER2+ mBC: Emerging Agents in the Third-Line and Higher Setting
Debu Tripathy, MD, discusses novel therapies being developed for later-line treatment of HER2+ mBC.
Read More
T-DXd: Updated Results from the DESTINY-Breast Studies and Practical Considerations for Followup
Drs McArthur and Telli discuss recent data updates from the DESTINY-Breast trials of T-DXd, including a pooled analysis, and share best practices for monitoring patients for lung complications.
Read More
Remaining Unmet Needs in the Third-Line and Lessons from HER2CLIMB
Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine.
Read More
Ongoing Second-Line Trials in Patients with HER2+ mBC and Expert Clinical Perspective
Panelists briefly touch on ongoing trials of second-line tucatinib combination therapy, including HER2CLIMB-02 and HER2CLIMB-05, in patients with or without brain metastases, and offer their clinical perspective which second-line regimens they typically recommend for their patients with HER2+ mBC.
Read More
Use of ADCs in the Second-Line Treatment of HER2+ mBC
Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.
Read More
Standard-of-Care and Emerging Therapies for First-line Treatment of HER2+ mBC
Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel regimens in the space.
Read More
Breast Cancer Management: Future Directions in Fertility Preservation
Closing out their discussion on fertility preservation in breast cancer, Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, look toward unmet needs and future evolutions in the treatment landscape and offer advice for community physicians.
Read More
Timing Fertility Preservation in Patients With Breast Cancer Undergoing Surgery
Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, review fertility preservation strategies in the context of patients with breast cancer undergoing surgery.
Read More
Data Updates and Ongoing Trials in the HER2+ Adjuvant Space
Panelists discuss recent data updates on standard-of-care and emerging regimens for adjuvant treatment of HER2+ eBC, including data presented at the 2023 ASCO meeting, and highlight exciting trials in progress that have not yet read out.
Read More
Identifying Patients Suitable for Adjuvant Neratinib
Drs Tripathy and McArthur touch on the use of extended adjuvant therapy with neratinib and identify patients who might be suitable for this regimen, including those high-risk patients with residual disease after neoadjuvant therapy.
Read More
Treatment Guidelines on Fertility Preservation in Breast Cancer
Focused discussion on treatment guidelines and recommendations for fertility preservation while treating premenopausal patients with breast cancer.
Read More
Monitoring Patients With Breast Cancer Receiving OFS
A brief review of monitoring, response assessment, and treatment modification strategies used for patients with breast cancer undergoing OFS. .
Read More